Diagnostics Platform Redcliffe Lifetech Rakes $61M Led LeapFrog Investment

Date:

A $61 million lead investment from LeapFrog Investments is a big win for diagnostics platform Redcliffe Lifetech. The funds will be used to scale the platform and expand its product portfolio. This investment will also help shift India’s health care focus away from cure to prevention. According to the company’s founder, preventive medicine is the future of health care in India.


Redcliffe Lifetech

LeapFrog is a VC firm focused on digital-first and asset-light business models. Its investments in healthcare are primarily aimed at improving access to diagnostic services and devices. In India, about 65% of the population lives in rural areas, and access to quality healthcare is difficult. With this funding, Redcliffe will expand its product offering to include radiology and disease data profiling, as well as lifestyle management.

The investment round was led by LeapFrog Investments, with participation from Healthquad, Schroders, Growth Spark Ventures, Alkemi Venture Partners, and LC Nueva. Redcliffe Lifetech plans to use the funds to expand its geographic reach, hire more physicians, and improve its software. The company also plans to use the new funding to expand its platform to more cities.

The company has also raised $70 million led by Chiratae Ventures, whose portfolio includes many startups in the healthcare space. The investment is aimed at accelerating the adoption and implementation of advanced automation solutions in the $400 billion post-acute care market. Redcliffe also recently closed a pre-Series A financing round led by Tiger Global. With the latest financing, the company plans to expand its team and acquire other companies in the space.


LeapFrog Investments

LeapFrog Investments led a $61 million Series B funding round for diagnostics platform Redcliffe Lifetech. The company offers a broader portfolio of tests, and its omnichannel platform includes more than 400 phlebotomists at more than 100 locations. The company’s claims services are 25-60 percent less expensive than competitors’.

The investment round was led by LeapFrog Investments, with participation from Healthquad, Schroders, Growth Spark Ventures, Chiratae Venture Partners, and Alkemi Venture Partners. The startup will use the funds to expand into Tier II and III cities and scale its platform. It plans to expand into new markets, such as Tier II and Tier III cities, to bring affordable pathology services to millions of households. This round of funding is the latest round of investment for the company, which now has annualized revenue of about $55 million to $60 million.

MUST READ Simple Tips And Tricks To Help You In The Real Estate Market

The funding will help Redcliffe expand geographically throughout India and expand its product portfolio. Redcliffe is focusing on low-cost, high-quality Direct-to-Consumer diagnostics for consumers and healthcare professionals. Its core products include glucose testing and pathology services, and the company will use the funding to scale its platform. It plans to expand its product offerings to include other fields, such as imaging and disease data profiling.


Automation-as-a-service solution provider Element5

Automation-as-a-service solution company Element5 has raised $61 million from investors led by LeapFrog Investment. The round also included investments from Healthquad, Schroders, Growth Spark Ventures, Alkemi Venture Partners, and others. The company plans to use the funds to expand its geographic footprint and boost its product team. Element5 says its latest strategic investment is aimed at accelerating the deployment of its advanced automation solutions in the post-acute care market.


Zepto

New funding round adds to growth for Agritech startup Zepto Diagnostics. The company has raised more than $60 million and is now valued at more than $1 billion. Zepto recently closed a $200 million financing round. With the new funding, the company has nearly doubled its valuation. Founded in 2014, Zepto has raised more than six times its initial seed funding.


Absolute

Redcliffe Lifetech, a company specializing in affordable blood testing, has raised $61 million from LeapFrog Investments. Other investors included Healthquad, Schroders, Growth Spark Ventures, and Alkemi Venture Partners. In its Series A round, Redcliffe raised $10 million. Redcliffe plans to use the capital to expand geographically and expand its product offerings. Its founder Dheeraj Jain said that the company has an annual revenue of between $55 and $60 million.

Element5 said the company’s latest strategic investment will focus on scaling its post-acute care automation solutions. The company has raised $5 million in seed funding and has raised a further $11.5 million from existing investors. This funding round will allow the company to expand its reach and expand its team in order to serve more patients. The latest round of funding will also help the company expand its sales and marketing efforts.


Neobank

LeapFrog Investments, a global co-leader in healthcare investments, has invested in the Australian startup Redcliffe Lifetech. The company specializes in genetics and pathology tests for patients, and it offers over 3,500 tests at a price that is affordable for everyone. With these new investments, Redcliffe will be able to expand its services beyond the traditional health insurance industry and into the growing digital health market.

LeapFrog Investments led a $61 million round of funding for the diagnostics platform Redcliffe Lifetech. Other investors included Healthquad, Schroders, Growth Spark Ventures, and Chiratae Ventures. The company plans to use the funds to expand to tier II and tier III cities across India and scale its platform. This latest round follows two prior funding rounds from Chiratae Ventures and LeapFrog Investments.

The investment will enable Redcliffe to expand its current offerings in reproductive health testing, genetic disorders, and cancer gene diagnostics. The company has in-house technology and offers counseling services and clinical data management to help patients find the best treatment options. Neobank is also looking to invest in healthcare technology and is planning to launch several new products in the near future. The startup has raised $187 million to date and aims to disburse a total of $1 billion through these products.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

ERP Modules: Types and Characteristics

Multiple options might be discovered while examining business management...

Agritech start-up Otipy is appointing Rohit Sood as its chief executive officer

Rohit Sood has been selected to be the chief...

Nykaa Q2: Profits up 333% year-over-year to the sum of Rs 5.2 crore Revenue up 39%

The second quarter in the fiscal year currently in...

Decentro is a fintech company has received $4.7M in the Series A round of capital

Funded by Y Combinator, a banking and payments API...